Annual Report

Overview

The report reviews 2019 progress across OBI's oncology drug pipeline, including phase III work and clinical development milestones. It reports only NT$872 thousand of operating income, primarily from Difucid royalty recognition, while research and development expenses remained substantial. The CSR disclosures describe laboratory waste controls, energy-saving measures, employee welfare, safety training, and integrity policies. The report also states that external assurance of the CSR report had not been carried out.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Period: 1 January 2019 – 31 December 2019
Publication date: 30 April 2020
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services